Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management
For this supplement, the expert faculty provided detailed perspectives on the evolving role of isatuximab in the multiple myeloma treatment paradigm, including their point of view on recent data from the phase 3 GMMG HD7 study and the cost implications for the use of isatuximab-based regimens in myeloma, along with their overall impressions of the current costs of myeloma care and treatment.
Supported through funding from
MM is a clonal malignancy of terminally differentiated
plasma cells, characterized by the accumulation of malignant
cells in the bone marrow. Read More ›
Isatuximab is 1 of the 2 FDA-approved anti-CD38 monoclonal antibodies used to treat patients with multiple myeloma. Read More ›
As providers and payers, we recognize that the costs of treating multiple myeloma are some of the highest among all disease states. Read More ›